Lawrence E. Feldman, MD
Combinations with checkpoint inhibitors and chemotherapy have become a standard therapeutic choice for some patients with non–small cell lung cancer (NSCLC), and such regimens continue to be explored in other subtypes—showing benefit in those with high tumor mutational burden (TMB) and squamous cell disease.
on NSCLC, Feldman, professor of Clinical Medicine at the University of Illinois, Chicago, discussed exciting new data surrounding immunotherapy combinations in the lung cancer.
OncLive®: Please provide an overview of your presentation on immunotherapy combinations in lung cancer.
: I discussed the immunotherapy combinations, nivolumab and ipilimumab, and durvalumab (Imfinzi) and tremelimumab. I also discussed data pertaining to combinations consisting of chemotherapy and immunotherapy, particularly the KEYNOTE-189 study that was recently presented at the 2018 ASCO Annual Meeting, which showed an overall survival advantage with pembrolizumab added to carboplatin/pemetrexed compared with chemotherapy alone.
What are the combinations being evaluated in this space and what new data are being reported?
The CheckMate-026 trial retrospectively showed that when we looked at patients with high TMB versus those with low to medium TMB, the patients with high TMB had a longer PFS when they received frontline nivolumab versus chemotherapy.
... to read the full story